drugset / Trial / NCT01635985

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

NCT01635985

Phase 1 Completed 18 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to look at drug levels of AZD5423 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with four different devices), to healthy subjects

Timeline

Start
2012-08
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5423 Other / unclassified 200 ug Intravenous
Subject AZD5423 Other / unclassified 250 ug Intravenous
Subject AZD5423 Other / unclassified 300 ug Intravenous
Subject AZD5423 Other / unclassified 1200 ug Intravenous

Indications

No indication recorded.